Isfahan University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Cutaneous Necrosis After the Injection of Sodium Stibogluconate for the Treatment of Cutaneous Leishmaniasis: A Rare Case Report Publisher



Abtahinaeini B1 ; Hakamifard A2 ; Sahraei Z3 ; Hadian M4 ; Saffaei A3
Authors
Show Affiliations
Authors Affiliations
  1. 1. Skin Diseases and Leishmaniasis Research Center, Isfahan University of Medical Sciences, Isfahan, Iran
  2. 2. Department of Infectious Diseases, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
  3. 3. Department of Clinical Pharmacy, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran
  4. 4. School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

Source: Journal of Isfahan Medical School Published:2019


Abstract

A 32-year-old man was diagnosed with cutaneous leishmaniasis, and intradermal Sodium Stibogluconate was injected for him. After two days, the injection site became erythematous, and a progressive necrotizing lesion appeared; hence, the patient diagnosed with soft tissue infection. Antibiotic therapy and debridement initiated for him. Cutaneous adverse effect of Sodium Stibogluconate is not common, and among them, coetaneous necrosis is rare. Sodium Stibogluconate is a mixture of complex compound, and it is not a simple medicine. A probable mechanism of necrosis formation in this case is hypersensitivity reactions. Hence, it is suggested to avoid intradermal injection of this medicine, especially those brands which do not claim intradermal injection allowance. © 2019, Isfahan University of Medical Sciences(IUMS). All rights reserved.
Related Docs
View other Related Docs
1. Treatment of Cutaneous Leishmaniasis With Ketoconazole Cream, Journal of Dermatological Treatment (2003)
2. The Efficacy of Treatment With Intralesional Meglumine Antimoniate Alone, Compared With That of Cryotherapy Combined With the Meglumine Antimoniate or Intralesional Sodium Stibogluconate, in the Treatment of Cutaneous Leishmaniasis, Annals of Tropical Medicine and Parasitology (2003)
3. Distribution Frequency of Pathogenic Bacteria Isolated From Cutaneus Leishmaniasis Lesions, Korean Journal of Parasitology (2008)
4. Treatment of Recurrent Cutaneous Leishmaniasis, International Journal of Dermatology (1995)
5. Efficacy of Paromomycin Ointment in the Treatment of Cutaneous Leishmaniasis: Results of a Double-Blind, Randomized Trial in Isfahan, Iran, Annals of Tropical Medicine and Parasitology (2005)
6. Effect of Combination Therapy With Systemic Glucantime and Pentoxifylline in the Treatment of Cutaneous Leishmaniasis, International Journal of Dermatology (2006)
7. Preparation and Evaluation of Clinical Effects of Glucantime Gel Mask, Journal of Isfahan Medical School (2013)
8. Comparative Effect of Topical Trichloroacetic Acid and Intralesional Meglumine Antimoniate in the Treatment of Acute Cutaneous Leishmaniasis, International Journal of Pharmacology (2006)
Experts (# of related papers)
View all Related Experts
Seyed Hossein Hejazi (27)
Ali Asilian (13)
Other Related Docs
9. The Skin Side Effects of Topical Glucantime in Patients With Cutaneous Leishmaniasis, Journal of Isfahan Medical School (2015)
10. Comparison of Intralesionally Injected Zinc Sulfate With Meglumine Antimoniate in the Treatment of Acute Cutaneous Leishmaniasis, Dermatology (2004)
11. Interleukin-10 and Transforming Growth Factor-Β in Early and Late Lesions of Patients With Leishmania Major Induced Cutaneous Leishmaniasis, Iranian Journal of Parasitology (2012)
12. Study of Il-12 Agonists in Macrophages From Patients With Healing and Non-Healing Forms of Cutaneous Leishmaniasis, Journal of Isfahan Medical School (2013)
13. Pcr-Rflp Diagnosis and Characterization of Leishmania Species Causing Human Cutaneous Leishmaniasis and Evaluation of Treatment Times With Glucantime in These Patients, Tropical Biomedicine (2016)
14. The Effect of Intralesional Meglumine Antimoniate (Glucantime) Versus a Combination of Topical Trichloroacetic Acid 50% and Local Heat Therapy by Non-Ablative Radiofrequency on Cutaneous Leishmaniasis Lesions, Journal of Research in Medical Sciences (2012)
15. A Comparative Study Between the Efficacy of Systemic Meglumine Antimoniate Therapy With Standard or Low Dose Plus Oral Omeprazole in the Treatment of Cutaneous Leishmaniasis, Journal of Vector Borne Diseases (2008)
16. Treatment of Cutaneous Leishmaniasis With Aminosidine (Paromomycin) Ointment: Double-Blind, Randomized Trial in the Islamic Republic of Iran, Bulletin of the World Health Organization (2003)
17. Comparative Study of the Efficacy of Combined Cryotherapy and Intralesional Meglumine Antimoniate (Glucantime®) Vs. Cryotherapy and Intralesional Meglumine Antimoniate (Glucantime®) Alone for the Treatment of Cutaneous Leishmaniasis, International Journal of Dermatology (2004)
18. Behaviors and Perceptions Related to Cutaneous Leishmaniasis in Endemic Areas of the World: A Review, Acta Tropica (2021)
19. Aquaglyceroporin1 Gene Expression in Antimony Resistance and Susceptible Leishmania Major Isolates, Journal of Vector Borne Diseases (2016)
20. Anti-Leishmania Activity of Osthole, Pharmacognosy Research (2016)
21. Treatment of Acute Cutaneous Leishmaniasis With Intralesional Injection of Meglumine Antimoniate: Comparison of Conventional Technique With Mesotherapy Gun, International Journal of Dermatology (2010)
22. Treatment of Cutaneous Leishmaniasis With Itraconazole: Randomized Double-Blind Study, Archives of Dermatology (1996)
23. Identification of Leishmania Species and Treatment Courses in Patients With Leishmaniasis in Isfahan, Iran, Journal of Isfahan Medical School (2012)
24. Recombinant C-Reactive Protein: A Potential Candidate for the Treatment of Cutaneous Leishmaniasis of Balb/C Mice Caused by Leishmania Major, Acta Parasitologica (2021)
25. Topical Effectiveness of Different Concentrations of Nanosilver Solution on Leishmania Major Lesions in Balb/C Mice, Journal of Vector Borne Diseases (2012)
26. Treatment of Cutaneous Leishmaniasis: Cassia Fistula Fruit Gel-Intralesional Glucantime Vs. Placebo Gel- Intralesional Glucantime Combination, Tehran University Medical Journal (2010)
27. Serum Monocyte Chemotactic Protein-1 and Nitric Oxide in Cutaneous Leishmaniasis Patients Before and After Treatment With Glucantime, Journal of Isfahan Medical School (2012)
28. Therapeutic Effect of Topical Tamoxifen in Murine Cutaneous Leishmaniasis Caused by Leishmania Major, Antimicrobial Agents and Chemotherapy (2024)
29. A Randomised, Double-Blind, Controlled Trial of a Killed L. Major Vaccine Plus Bcg Against Zoonotic Cutaneous Leishmaniasis in Iran, Vaccine (1999)
30. Bacterial Superinfection in Zoonotic Cutaneous Leishmaniasis, Medical Science Monitor (2012)
31. Electrocardiographic Changes in Patients With Cutaneous Leishmaniasis Treated With Systemic Glucantime, Annals of the Academy of Medicine Singapore (2008)
32. The Efficacy of 5% Trichloroacetic Acid Cream in the Treatment of Cutaneous Leishmaniasis Lesions, Journal of Dermatological Treatment (2012)
33. A Comparison Between the Effects of Glucantime, Topical Trichloroacetic Acid 50% Plus Glucantime, and Fractional Laser Plus Glucantime on Cutaneous Leishmaniasis Lesions, Journal of Isfahan Medical School (2013)
34. The Study of the Inhibitory Effects of Aqueous and Ethanolic Extracts of Ziziphora Tenuior L. on the Proliferation of Leishmania Major Amastigotes, Iranian Journal of Dermatology (2018)
35. Heat Therapy for Cutaneous Leishmaniasis: A Literature Review, Journal of Research in Medical Sciences (2021)
36. Effect of Adjunctive Topical Liposomal Azithromycin on Systemic Azithromycin on Old World Cutaneous Leishmaniasis: A Pilot Clinical Study, Iranian Journal of Pharmaceutical Research (2021)
37. Effect of Topical Honey Application Along With Intralesional Injection of Glucantime in the Treatment of Cutaneous Leishmaniasis, BMC Complementary and Alternative Medicine (2007)
38. Study of Therapeutic Effect of Different Concentrations of Imatinib on Balb/C Model of Cutaneous Leishmaniasis, AIMS Microbiology (2020)
39. Evaluation of Leishmanin Skin Test Reaction in Different Variants of Cutaneous Leishmaniasis, Indian Journal of Dermatology (2013)
40. In Vitro Effects of Turmeric and Licorice Total Extracts on L. Major Promastigotes, Journal of Isfahan Medical School (2012)
41. Demographic and Clinical Characteristics of Children With Cutaneous Leishmaniasis in Isfahan Province, Iran, During 2011-2015, Journal of Isfahan Medical School (2017)
42. Anti-Leishmaniasis Effect of Staphylococcus Aureus Protein a on the Size of the Lesion and Parasitic Load, Advanced Biomedical Research (2023)
43. Evaluation of Leishmanin Skin Test and Its Relationship With the Clinical Form and Duration of Cutaneous Leishmaniasis, Dermatology Online Journal (2006)
44. Isolation of Bacteria Causing Secondary Bacterial Infection in the Lesions of Cutaneous Leishmaniasis, Indian Journal of Dermatology (2008)
45. Clinical Picture of Cutaneous Leishmaniasis in Isfahan, Iran, International Journal of Dermatology (1994)
46. Vaccination in Leishmaniasis: A Review Article, Iranian Biomedical Journal (2022)
47. Efficacy of Adjunctive Topical Liposomal Clarithromycin on Systemic Glucantime in Old World Cutaneous Leishmaniasis: A Pilot Clinical Study, Frontiers in Pharmacology (2023)
48. Treatment of Glucantim™-Resistant Cutaneous Leishmaniasis Using Combination Therapy of Allopurinol and Trichloroacetic Acid (Tca) 50%; Report of Three Cases, Journal of Isfahan Medical School (2017)
49. Immune Response Measured in Human Volunteers Vaccinated With Autoclaved Leishmania Major Vaccine Mixed With Low Dose of Bcg, Clinical and Experimental Immunology (2003)
50. Exposure to Leishmania Major Modulates the Proportion of Cd4+ T Cells Without Affecting Cellular Immune Responses, Microbiology and Immunology (2007)